Request Demo
Last update 04 Apr 2026
Efpegsomatropin
Last update 04 Apr 2026
Overview
Basic Info
Drug Type Peptide Hormone |
Synonyms LAPS-hGH, LAPS-rhGH, HM-10560A |
Target |
Action agonists |
Mechanism GHR agonists(Growth hormone receptor agonists) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
RegulationOrphan Drug (European Union) |
Login to view timeline
Structure/Sequence
Sequence Code 9133009
Source: *****
Sequence Code 26401985
Source: *****
Related
2
Clinical Trials associated with EfpegsomatropinNCT01822340
A Phase II, Randomized, Active Controlled, Open Label Study of Safety and Efficacy of HM10560A a Long-acting rhGH-HMC001 Conjugate in Treatment of Subjects Suffering From Adult Growth Hormone Deficiency (AGHD)
NCT01093742
A Dose Block-randomized, Double-blind, Placebo-controlled, Single Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of HM10560A After S.C. Administration in Healthy Male Subjects
100 Clinical Results associated with Efpegsomatropin
Login to view more data
100 Translational Medicine associated with Efpegsomatropin
Login to view more data
100 Patents (Medical) associated with Efpegsomatropin
Login to view more data
100 Deals associated with Efpegsomatropin
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Growth hormone deficiency | Phase 2 | Bulgaria | 12 Sep 2011 | |
| Growth hormone deficiency | Phase 2 | India | 12 Sep 2011 | |
| Growth hormone deficiency | Phase 2 | Poland | 12 Sep 2011 | |
| Growth hormone deficiency | Phase 2 | Romania | 12 Sep 2011 | |
| Growth hormone deficiency | Phase 2 | Russia | 12 Sep 2011 | |
| Growth hormone deficiency | Phase 2 | Serbia | 12 Sep 2011 | |
| Growth hormone deficiency | Phase 2 | South Korea | 12 Sep 2011 | |
| Growth hormone deficiency | Phase 2 | Ukraine | 12 Sep 2011 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free